Post-Marketing Surveillance of Adalimumab in Korean Hidradenitis Suppurativa Subjects (HS rPMS)

AbbVie

Status: Completed

Conditions: Hidradenitis Suppurativa (HS)

Study type: Observational

Funder types: Industry

Identifiers

NCT03001115

P16-052

Details and patient eligibility

About

The objective of this study is to evaluate the safety profile of Adalimumab for Hidradenitis Suppurativa (HS) participants in normal medical practice.

Enrollment: 17 patients

Sex: All

Ages: 18 to 99 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Participant who are eligible to be treated with adalimumab for HS in accordance with the approved Korean label
• Participant must provide written authorization form to use their personal health data prior to the participating in the study.

Exclusion criteria

• Participant who are contraindications to adalimumab as listed on the approved Korean label.
• Participant who is participating on other clinical trials.

Trial design

17 participants in 1 patient group

Participants with Hidradenitis suppurativa (HS)

Description:

Participants with HS treated with adalimumab (HUMIRA®) in routine clinical practice.